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Background & aims: A recent meta-analysis showed that supplementation of omega-3 fatty acids in
parenteral nutrition (PN) regimens is associated with a statistically and clinically signiﬁcant reduction in
infection rate, and length of hospital stay (LOS) in medical and surgical patients admitted to the ICU and
in surgical patients not admitted to the ICU. The objective of this present study was to evaluate the cost-
effectiveness of the addition of omega-3 fatty acids to standard PN regimens in four European countries
(Italy, France, Germany and the UK) from the healthcare provider perspective.
Methods: Using a discrete event simulation scheme, a patient-level simulation model was developed,
based on outcomes from the Italian ICU patient population and published literature. Comparative efﬁcacy
data for PN regimens containing omega-3 fatty acids versus standard PN regimens was taken from the
meta-analysis of published randomised clinical trials (n ¼ 23 studies with a total of 1502 patients), and
hospital LOS reduction was further processed in order to split the reduction in ICU stay from that in-ward
stays for patients admitted to the ICU. Country-speciﬁc cost data was obtained for Italian, French, German
and UK healthcare systems. Clinical outcomes included in the model were death rates, nosocomial
infection rates, and ICU/hospital LOS. Probabilistic and deterministic sensitivity analyses were under-
taken to test the reliability of results.
Results: PN regimens containing omega-3 fatty acids were more effective on average than standard PN
both in ICU and in non-ICU patients in the four countries considered, reducing infection rates and overall
LOS, and resulting in a lower total cost per patient. Overall costs for patients receiving PN regimens
containing omega-3 fatty acids were between V14 144 to V19 825 per ICU patient and V5484 to V14 232
per non-ICU patient, translating into savings of between V3972 and V4897 per ICU patient and savings of
between V561 and V1762 per non-ICU patient. Treatment costs were completely offset by the reduction
in hospital stay costs and antibiotic costs. Sensitivity analyses conﬁrmed the robustness of these ﬁndings.
Conclusions: These results suggest that the supplementation of PN regimens with omega-3 fatty acids
would be cost effective in Italian, French, German and UK hospitals.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).adelli), mario.eandi@unito.it
, Konstantin.Mayer@uglc.de
Muscaritoli), Axel.Heller@
chaffner@fresenius-kabi.com
Ltd. This is an open access article u1. Introduction
In Italy, France, Germany and the UK, a substantial part of hos-
pital budgets is dedicated to ICU costs, owing to the technological
and personnel resources required.
Critically ill and surgical patients receive parenteral nutrition
(PN) when oral or enteral nutrition is impossible, insufﬁcient, or
contra-indicated. Interest in omega-3 fatty-acid rich ﬁsh oil-nder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
L. Pradelli et al. / Clinical Nutrition 33 (2014) 785e792786containing lipid emulsions as part of a PN regimen has increased in
recent years, with the recognition that they supply not only energy
and essential fatty acids, but also very long-chain fatty acids,
especially eicosapentaenoic acid (EPA) and docosahexaenoic acids
(DHA), which are considered to be clinically beneﬁcial.
A meta-analysis conducted on 23 studies e thirteen conducted
in 762 patients admitted to an ICU, and ten in 740 elective surgical
patients, not admitted to ICU1 e showed that the use of ﬁsh oil-
containing lipid emulsions as part of a PN regimen was associated
with statistically signiﬁcant and clinically relevant reductions in
infection rate and of hospital and (where appropriate) ICU lengths
of stay (LOS). Furthermore, supplementation with omega-3 fatty
acids confers important beneﬁts, including increased serum con-
centrations of alpha-tocopherol, increased EPA and DHA content of
phospholipids, and enhanced leucocyte activity, together with a
possible hepato-protective action (as evidenced by less elevation of
ALT and AST), and a signiﬁcantly greater reduction in interleukin-6
(IL-6) during the ﬁrst days after initiation of the PN regimen.
The aim of the present study was to evaluate the cost-
effectiveness of adding omega-3 fatty acids to standard PN regi-
mens by merging evidence on the clinical outcomes in the Italian
population with clinical effectiveness estimates from the afore-
mentioned international meta-analysis and health resource con-
sumption strategy in Italian hospitals. These cost-effectiveness
results for Italy were then extrapolated using health resource
consumption data from France, Germany and the UK in order to
judge whether difference clinical practices resulted in similar
pharmacoeconomic outcomes. The four national scenarios inves-
tigated represented different clinical practices for PN: in Italian and
French settings, three-chamber bags are used for PN; in the UK,
lipid emulsion units are used as a component of compounded PN
admixtures; in the German setting, both of these systems are used
(three-chamber bags or single bottles/bags).
2. Methods
For the present evaluation we used a decision analytic Discrete
Event Simulation (DES) pharmacoeconomicmodel that includes: (i)
outcomes from the Italian ICU patient population and from pub-
lished literature; (ii) partially re-elaborated efﬁcacy data from a
meta-analysis of published randomised clinical trials that included
23 studies with a total of 1502 patients receiving PN supplemented
with omega-3-rich fatty acids or PN standard regimens1; (iii) na-
tional Italian cost data; and (iv) extending these results to three
further national scenarios by using French, German and UK cost
data. Standard PN may be deﬁned as those containing non-
enriched lipid emulsions, namely, soybean oil, medium-chain tri-
glycerides/long-chain triglycerides or olive/soybean oil emulsions.
Please note that further details on the methods used in this study
are available as a Supplementary on-line appendix.
2.1. Italian model
2.1.1. Model structure
The model was built using a DES scheme designed with the use
of TreeAge Pro 2009 (TreeAge Software Inc., Williamstown, MA)
software. In a DES, changes in the individuals’ state are modelled
over time in terms of events that occur and the consequences of
those events. This DES strategy, rather than aMarkovmodel, is used
as it is particularly suitable for non-chronic situations where the
timing and chronology of events are important, such as in patient
groups under consideration in this study (surgical and ICU patient
populations given PN).
The model simulates two treatment alternatives for patients
needing PN: parenteral omega-3 enriched emulsions or standardlipid emulsions. Moreover, two patient populations are considered
in this study: (i) medical and surgical patients with an ICU stay and
(ii) surgical patients without an ICU stay. The following events are
considered: transfers between ICU and ward, nosocomial in-
fections, discharge from the hospital, and death, with the last two
events determining the end of treatment. A simpliﬁed model
structure is shown in Fig.1(a) and (b) (for ICU and non-ICU patients,
respectively). For ICU patients the publicly available Progetto Mar-
gherita report data are used as this is extensive and representative
of the ICU population, but no such comparable source is available
for non-ICU patients, therefore we used international clinical trial
data for this population.2e72.1.2. Probability and outcomes
The main clinical outcomes simulated by the model are: death
rate in the ICU, infection rate in the ICU, death rate in the ward, and
length of hospital stay (LOS) which is divided into LOS pre-ICU, LOS
in the ICU, and LOS in the ward (post-ICU for ICU patients).
The data source used for estimating the probability distributions
of these outcomes in the ICU population is the 2009 edition of the
Progetto Margherita report, an annual publication on behalf of the
Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva
(GIVITI) that includes data collected in 230 Italian ICUs from a total
of over 77 000 patients.8 The GIVITI network, which covers more
than half of all ICUs operating in Italy, is coordinated at the Mario
Negri Institute of Pharmacology in Milan, and conducts constant
monitoring of the activities and outcomes of participating ICUs.
These range frommedium to large in scale, university-afﬁliated and
non-university-afﬁliated ICUs, and reﬂect the range of ICUs found
in Italy. Data are collected at the patient level using standardised
computer software.
The outcomes after ICU admission for this population are: (i)
death in ICU (19.0%); (ii) transfer to a general ward (79.7%), or (iii)
discharge from the ICU directly to home (1.3%). Among patients
transferred to the general ward after ICU discharge, the mortality
rate is 7.9%. In this patient population, the risk of new nosocomial
infections acquired in the ICU is 11.4%. For the elective surgical
population, the outcomes are: (i) death in the ward (4.76%) or (ii)
discharge fromward (95.24%), and the risk of nosocomial infections
is 23.0%: these represent weighted averages of the control groups
included in the recent meta-analysis.1
The Progetto Margherita reports detailed information regarding
hospital and ICU lengths of stay, with data given for the overall
population and for subgroups of ICU/hospital outcomes. Distribu-
tion curves were ﬁtted to these data to mathematically represent
these distributions in the model, giving simulation input data for
ICU patients (as shown in Table 1). For non-ICU patients, the same
curve-ﬁtting procedure was applied to data from the literature.2e7
The times-to-events applied to the simulated patients are drawn
from these ﬁtted distributions.2.1.3. Simulation and sensitivity analysis
In our model, the simulation takes into account the variability
among individuals, while the probabilistic sensitivity analysis
(PSA) allows us to consider the uncertainty of key parameters and
its effect on the estimated outcomes, verifying the robustness of
the numerical outcomes. This was done using a two-level Monte
Carlo simulation. A deterministic sensitivity analysis (DSA) was
also used. This allows us to investigate which input parameters
had the greatest impact on incremental total cost and LOS. The
parameters employed in the PSA and DSA analyses and their
related distributions are reported in Tables 1and 2. Further details
on the simulation and these sensitivity analyses is provided in the
Supplementary on-line appendix.
ab
Fig. 1. a. Simpliﬁed model structure for ICU patients. b. Simpliﬁed model structure for non-ICU patients.
Table 1
a. Clinical outcomes for ICU patients in the control group used for the simu-
lation. b. Clinical outcomes for non-ICU patients in the control group used for
the simulation.
a)
Parameter (unit) Mean (SD)
LOS pre-ICU (days) 5.6 (9.91)
LOS ICU alive (days) 6.1 (11.40)
LOS ICU dead (days) 8.8 (16.0)
LOS post ICU alive (days) 13.7 (14.6)
Death risk in ICU 0.19
Probability ICU-ward transfer 0.80
Probability ICU-home discharge 0.01
Death risk in ward 0.08
Baseline infection rate 0.11 (0.02)
Patient bodyweight (kg) 70.13 (14.47)
Duration of PN (days) 6.13 (4.77)
b)
Parameter (unit) Mean (SD)
LOS (days) 17.4 (10.26)
Death risk 0.05
Baseline infection rate 0.23 (0.05)
Patient bodyweight (kg) 60.98 (10.93)
Duration of PN (days) 5.94 (1.59)
PN, parenteral nutrition; LOS, length of stay; SD, standard deviation.
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The model includes the costs in Italy for PN, ICU and general
ward stays, and cost of nosocomial infections acquired in the ICU.
All costs were updated to reﬂect 2011 costs (Table 2).
The cost of PN is calculated for each individual as the product of
the daily cost, depending on the patientweight, treatment assigned,
and the duration of PN. Costs of PN are weighted according to the
utilisation ratios of the two types of packaging systems for both ICU
(fraction of three-chamber bags used¼ 0.52) and non-ICU (fraction
of three-chamber bags used¼ 0.69) patients. For omega-3 fatty acid
enriched PN, national public acquisition price for the three-
chamber bag product (SmofKabiven, manufactured by FreseniusTable 2
Italian, French, German and UK cost parameters employed in the model (costs
updated to 2011).
Cost
parameters
Italy
(V)
France
(V)
Germany (V) UK (£) UK (Va)
Daily cost ICU 15689 134912 133613 1435e258314 1765e3177
Daily cost ward 77510 84415 49316 266e31917 327e392
Cost of infection 109311 372318 2292e326419 44120 542
Note: numbers in parentheses are reference numbers.
a Euro values are given for the UK to allow comparison with Eurozone countries
(exchange rate V1.23 ¼ £1, August 2012).
Table 3
Effect on hospital length of stay (LOS) and infection rate based on model simulations for standard (ST) and omega-3 enriched (ST þ U3) parenteral nutrition treatments.
Mean [95% CI] ICU patients Non-ICU patients
ST þ U3 ST Difference ST þ U3 ST Difference
LOS e total (days) 18.59 [11.82;19.38] 23.06 [22.11;24.15] L4.55 [L4.79;L4.29] 15.70 [15.65;16.05] 17.29 [17.20;17.60] L1.58 [L1.61;L1.49]
Infections/10 000 patients 827 [477;1135] 1086 [674;1596] L259 [L480;L178] 1201 [754;1686] 2391 [1410;3186] L1189 [L1511;L645]
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rable three-chamber bags were considered for standard PN.
For each possible patient weight the daily cost for each brand
has been calculated by choosing the smallest sufﬁcient content, on
a basis of a lipid intake of 1.3 g fat/kg BW/day. The daily cost for each
patient weight was then calculated byweighting the product prices
according to their national market shares. Individual patient
weights in the model are sampled from distributions reﬂecting the
Progetto Margherita population for ICU patients, and the pop-
ulations enrolled in the clinical trials included in our earlier meta-
analysis for patients not admitted to an ICU.
In order to estimate the average daily cost of Italian ICUs, we
relied on the results of prospective case-control studies. For Italy,
the results by Tarricone9 yield a value ofV1498 (2011 valueV1568),
after subtracting the costs for surgical procedures and for extra
antibiotics in their sepsis patients, considered separately for pa-
tients developing nosocomial infections in the simulation.
The average daily cost of a hospital ward was taken from the
2005 report of the National Agency for Regional Health Services10
for Italy. This estimate includes ﬁxed overhead costs of heating,
lighting, laundry, provision of food for patients, and average costs
for medicines and staff, actualised to 2011 values of V775.
Nosocomial infections acquired in the ICU signiﬁcantly increase
overall hospital costs, mainly from the prolongation of hospital LOS.
Since the effect of omega-3 fatty acid supplementation on the
infection rate is already modelled in terms of the reduction of the
average LOS, we chose not to include an extra effect on the LOS
resulting from the reduced infection rate in order to avoid double
counting. Thus, we limited the cost of any new infection to that of
the additional antibiotics needed. We employed the average
infection cost reported by Orsi et al.11 in Italy for the treatment of
ICU-emergent bloodstream infections, actualised to a 2011 value of
V1093.2.2. Extension of the model to France, Germany and the UK
The model was extended to encompass the costs for each of the
three other markets of interest (France, Germany and UK) for PN,
ICU and general ward stays, and cost of nosocomial infections ac-
quired in the ICU.12e20 All costs were updated to reﬂect 2011 costsTable 4
Costs based on model simulations for standard (ST) and omega-3 enriched (ST þ U3) pa
Mean [95% CI] ICU patients
ST þ U3 ST Difference
Italy (V)
Total 19 825 [14 847;25 191] 24 504 [18 266;31 265] L4679 [L6121
ICU 7475 [4698;10 607] 10 166 [6389;14 415] L2691 [L3812
Ward (pre-ICU) 4318 [2703;6076] 4318 [2703;6076] 0 [0;0]
Ward 6336 [3799;8912] 8531 [5102;11 972] L2195 [L3064
Infection 90 [37;139] 119 [52;196] L28 [L58;L14
Treatment 1605 [1442;1627] 1370 [1232;1394] 235 [203;240]
ICER (V/LOS day) Dominant
ICER, incremental cost-effectiveness ratio (U3 vs ST); LOS, length of stay.
Note: death rates per 10 000 patients are 2509 (ICU patients) and 511 (non-ICU patient(Table 2). Further details on these costs are outlined in the full
methods section within the Supplementary on-line appendix.
3. Results
3.1. Italy
Table 3 represents the effect on hospital LOS and infection rate
based on model simulations for standard and omega-3 enriched
PN. These base-case results were obtained by calculating outcomes
of interest for 10 000 simulated patients. Omega-3 fatty acid-
containing lipid emulsions are expected to be more effective than
standard PN, as they would prevent almost one quarter (259 of
1086) of infections in ICU patients and one-half (1189 of 2391) of
infections in non-ICU patients and reduce overall LOS.
Table 4 shows the base-case scenario for Italy for costs, based on
model simulations for standard and omega-3 enriched PN. Total
costs associated with a ﬁsh oil-based PN regimen are, on average,
lower than with standard PN with a mean cost saving per ICU and
non-ICU patient, respectively, of about V4700 and V1000 in Italy
(Table 4). These ﬁndings indicate that the extra cost for omega-3
fatty acid-containing PN is completely offset by the reduction in
hospital stay costs, and to a lesser extent by lower antibiotic costs
for the treatment of emergent infections. Indeed, inclusion of
omega-3 fatty acids in PN is expected to dominate standard PN
regimens on average, as it is associated with better clinical and
economic outcomes observed in 88% of ICU patients and in 68% of
non-ICU patients in Italy.
3.2. France, Germany and the UK
Base-case results for the effect on hospital LOS and infection
rates (based on model simulations for standard and omega-3
enriched PN) are the same as those found in the previous section
(see Table 3).
Total costs associated to a ﬁsh oil-based PN regimen are, on
average, lower than with standard PN, with a mean cost saving per
ICU and non-ICU patient, respectively, of about (i) V4900 and
V1800 in France (ii);V4000 andV1300 in Germany; and (iii) £4100
and £500 in the UK (Table 5). These ﬁndings indicate that the extrarenteral nutrition treatments: results for Italy.
Non-ICU patients
ST þ U3 ST Difference
;L3372] 13 595 [8832;18 663] 14 619 [9383;20 197] L1025 [L1540;L546]
;L1688] NA NA NA
NA NA NA
;L1300] 12 171 [7560;17 379] 13 399 [8299;19 086] L1228 [L1709;L737]
] 131[59;212] 261 [110;401] L130 [L190;L50]
1292 [1132;1152] 959 [836;848] 333 [293;307]
Dominant
s), regardless of treatment in all of the base-case scenarios.
Table 5
Costs based on model simulations for standard (ST) and omega-3 enriched (ST þ U3) parenteral nutrition treatments: results for France, Germany and the UK.
Mean [95% CI] ICU patients Non-ICU patients
ST þ U3 ST Difference ST D U3 ST Difference
France (V)
Total 18 964 [13 950;24 468] 23 861 [17 630;30 713] L4897 [L6287;L3637] 14 232 [9197;19 947] 15 994 [10 357;22 228] L1762 [L2319;L1123]
ICU 6427 [4039;9120] 8741 [5493;12 394] L2314 [L3277;L1451] NA NA NA
Ward (pre-ICU) 4705 [2945;6620] 4705 [2945;6620] 0 [0;0] NA NA NA
Ward 6903 [4139;9709] 9295 [5559;13 044] L2392 [L3339;L1416] 13 261[8237;18 935] 14 599 [9042;20 795] L1338 [L1862;L803]
Infection 308 [125;475] 404 [179;667] L96 [L198;L47] 447 [201;722] 890 [374;1366] L443 [L647;L170]
Treatment 621 [586;659] 716 [678;764] L96 [L107;L89] 524 [520;529] 505 [501;508] 19 [18,22]
ICER (V/LOS day) Dominant Dominant
Germany (V)
Total 14 144 [10 837;17 893] 18 117 [13 868;22 943] L3972 [L5084;L2996] 8841 [5842;12 078] 10 176 [6601;13 931] L1335 [L2116;L498]
ICU 6369 [3944;9120] 8662 [5360;12 393] L2293 [L3276;L1413] NA NA NA
Ward (pre-ICU) 2748 [1760;3798] 2748 [1760;3798] 0 [0;0] NA NA NA
Ward 4031 [2508;5592] 5428 [3369;7508] L1397 [L1918;L859] 7744 [4839;10 840] 8525 [5314;11 903] L781 [L1064;L474]
Infection 209 [L83;507] 274 [L117;713] L65 [L209;36] 392 [L423;1257] 780 [L800;2376] L388 [L1121;378]
Treatment 787 [748;837] 1005 [955;1072] L217 [L236;L205] 704 [698;709] 870 [865;876] L166 [L169;L164]
ICER (V/LOS day) Dominant Dominant
UK (£)
Total 13 333 [11 124;16 098] 17 463 [14 458;21 193] L4130 [L5103;L3326] 4674 [4336;5071] 5152 [4764;5571] L478 [L510;L418]
ICU 9208 [7018;11 987] 12 522 [9546;16 284] L3315 [L4302;L2522] NA NA NA
Ward (pre-ICU) 1593 [1457;1737] 1593 [1457;1737] 0 [0;0] NA NA NA
Ward 2338 [2025;2606] 3148 [2717;3500] L810 [L898;L689] 4491 [4152;4888] 4944 [4561;5367] L453 [L482;L406]
Infection 37 [15;58] 48 [21;82] L11 [L25;L6] 53 [23;84] 106 [44;159] L53 [L75;L20]
Treatment 158 [151;169] 152 [145;163] 6 [5,7] 130 [129;130] 102 [101;103] 28 [27;28]
ICER (£/LOS day) Dominant Dominant
UK (V)
Total 15 646 [13 054;18 890] 20 492 [16 966;24 869] L4846 [L5988;L3903] 5484 [5088;5950] 6045 [5590;6537] L561 [L599;L490]
ICU 10 805 [8236;14 066] 14 694 [11 201;19 109] L3890 [L5049;L2959] NA NA NA
Ward (pre-ICU) 1870 [1710;2039] 1870 [1710;2039] 0 [0;0] NA NA NA
Ward 2743 [2376;3058] 3694 [3189;4107] L950 [L1054;L808] 5270 [4872;5736] 5802 [5353;6298] L532 [L566;L476]
Infection 43 [17;68] 56 [24;96] L13 [L29;L7] 62 [27;99] 124 [51;186] L62 [L88;L24]
Treatment 186 [177;198] 178 [170;191] 7 [6,9] 152 [151;153] 120 [119;120] 32 [32;33]
ICER (V/LOS day) Dominant Dominant
ICER, incremental cost-effectiveness ratio (U3 vs ST); LOS, length of stay.
Note: death rates per 10 000 patients are 2509 (ICU patients) and 511 (non-ICU patients), regardless of treatment in all of the base-case scenarios.
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the reduction in hospital stay costs, and to a lesser extent by lower
antibiotic costs for the treatment of emergent infections. Indeed,
inclusion of omega-3 fatty acids in PN is expected to dominate
standard PN regimens on average, as it is associated with better
clinical and economic outcomes observed in 88e90% of ICU pa-
tients and in 71e73% of non-ICU patients in France, Germany, and
the UK.
3.3. Sensitivity analysis
The results of the PSA show that mean effectiveness and cost
estimates differ slightly from those resulting from the base-case
analysis, but the conclusions are consistent: total costs associated
with standard PN supplemented with omega-3 fatty acids are ex-
pected to be lower, while patient outcomes are anticipated to be
improved, as compared to standard PN. Consequently, omega-3
supplemented PN is expected to be more cost-effective than stan-
dard PN. In particular, it was observed that in all PSA simulations
omega-3 enriched PN was associated with clinical and economic
superiority, as depicted on the cost-effectiveness plane as a dot in
the ‘south-west’ quadrant. These results for Italy are shown in Fig. 2,
but very similar resultswere also found for France, Germany and the
UK (not shown). These results indicate the reliability of the main
conclusion regarding clinical and economic superiority. A careful
observation of the scatterplot (Fig. 2) also reveals a high degree of
correlation between cost and LOS savings, which is not surprising
given that hospital stay is one of the major drivers of costs.
DSA estimations conﬁrm that the cost difference between the
two treatments is mostly inﬂuenced by daily ward costs and LOSreduction in both ICU and non-ICU patients (Figs. 3 and 4, respec-
tively, for Italy). Note that very similar results were obtained for
other countries (not shown). Weight and lipid dose show a peculiar
effect, as variations in both directions result in reduced cost savings
with omega-3 supplementation. This depends on the difference
between PN daily cost in omega-3 and standard treatment; it is
lower in the base-case than in cases of weight or dose increases and
decreases. None of the variations that we tested changes the main
conclusion of the study: that on average, the addition of omega-3
fatty acids to the nutrition regimen is a cost-saving strategy.
(Although for ICU patients undergoing surgery and not admitted to
the ICU, dominance was lost when the upper limit of the credibility
interval for the relative ward LOS e which was above 1 e was
tested.)
4. Discussion and conclusions
In conclusion, the results of the present model indicate that the
addition of omega-3 fatty acids to standard PN regimens has the
potential to signiﬁcantly improve outcomes in both ICU and non-
ICU patients, while also leading to cost savings in Italian, French,
German, and UK hospitals. Themagnitude of the beneﬁts for adding
omega-3 fatty acids to standard PN regimens is also similar to those
reported in the literature. For example, we have reported re-
ductions in infection rates of approximately one quarter (ICU in-
fections) and one half (non-ICU infections). In Pradelli et al.1 ICU
infections were reduced by 29% and non-ICU infections by 47% (all
infections: RR 0.61; 95% CI 0.45e0.84; p< 0.05). Likewise themeta-
analysis of Chen et al.21 concerning ﬁsh-oil enriched parenteral
nutrition, showed a large and signiﬁcant reduction in postoperative
Fig. 3. Tornado plots representing the sensitivity of cost savings with omega-3 supplementation to variation in key parameters: ICU patients in Italy.
Fig. 2. Scatterplot of 1000 incremental cost-effective ratios (ICERs) (x2) estimates in the probabilistic sensitivity analysis (PSA) for Italy.
Fig. 4. Tornado plots representing the sensitivity of cost savings with omega-3 supplementation to variation in key parameters: non-ICU patients in Italy.
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0.98; p ¼ 0.04).
A possible limitation of the model is the heterogeneity in the
patient populations in the clinical studies included in the meta-
analysis. However, the patients, although admitted with a variety
of diagnoses, share the common pathophysiological feature of
imbalanced lipid mediators that favour a pro-inﬂammatory state,
which is ameliorated by omega-3 fatty acids. Other limitations of
the present study are inherent to the modelling approach in gen-
eral, in particular to the need for combining different data sources
into a single logical construct. The use of modelling in economic
evaluations is accepted as an unavoidable fact of life.22 In essence,
models can represent the complexity of the real world in a more
simple and comprehensible form, and are often used in health
economic evaluations where the relevant clinical trials have not
been conducted or did not include economic data capture. In these
cases decision analytic models are used to synthesise the best
available data.22 Decision models are particularly useful for
combining or linking data from different research areas and sources
and/or transferring or extrapolating results from one time, place,
population, or setting, to another.23 Modelling needs to used by
healthcare decision-makers as waiting until perfect information is
available is, in most cases, not a realistic option, and so costs and
consequences of a particular healthcare strategy need to be based
on available data.23
However, models can only be reliable if they are based on good-
quality evidence. In the current model, we used a mixture of
sources, including meta-analysis data. The use of meta-analysis
data is standard within pharmacoeconomic analyses, but poten-
tial drawbacks are that meta-analyses involve making judgements
onwhich studies to include and are generally only reliable if several
medium or large trials are included. Nevertheless, such analyses are
an opportunity to draw together all available and suitable data, to
increase sample size and thus the power to detect effects of
interest.
The overall value of the saving is quite consistent among the
settings analysed, although the contribution of the single cost items
is different, reﬂecting different hospital models across these Euro-
pean countries. This observation, coupled with the robustness of
model results in the sensitivity analyses (conducted to assess the
effect of parameter uncertainty), indicate our results may be gen-
eralisable to many different settings not speciﬁcally addressed in
this study.
In conclusion, the results of this modelling study strongly sug-
gest that the addition of omega-3 fatty acids to standard PN is a
clinically and economically attractive strategy, representing a ‘wine
win’ scenario for both patients and healthcare providers. This is
because supplementation of lipid emulsions with omega-3 fatty
acids reduces infection rates and length of hospital stay in ICU and
in non-ICU patients receiving PN. As a consequence, supplementary
treatment costs are completely offset by the reduction in the cost of
hospital stay and antibiotics. As such, the results of the model show
that supplementation of lipid emulsions with omega-3 fatty acids is
highly likely to lead to cost savings in Italian, French, German, and
UK hospitals.
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